CN105188715B - Mir-145的锁定核酸抑制剂及其用途 - Google Patents

Mir-145的锁定核酸抑制剂及其用途 Download PDF

Info

Publication number
CN105188715B
CN105188715B CN201480015816.XA CN201480015816A CN105188715B CN 105188715 B CN105188715 B CN 105188715B CN 201480015816 A CN201480015816 A CN 201480015816A CN 105188715 B CN105188715 B CN 105188715B
Authority
CN
China
Prior art keywords
oligonucleotide
mir
oligonucleotides
pharmaceutical composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480015816.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105188715A (zh
Inventor
A.G.塞托
E.V.罗伊
K.H.鲁宾逊
C.M.多尔比
T.G.赫林格
R.蒙哥马利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meter La Gen Medical Treatment Limited-Liability Co
Original Assignee
Meter La Gen Medical Treatment Limited-Liability Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meter La Gen Medical Treatment Limited-Liability Co filed Critical Meter La Gen Medical Treatment Limited-Liability Co
Publication of CN105188715A publication Critical patent/CN105188715A/zh
Application granted granted Critical
Publication of CN105188715B publication Critical patent/CN105188715B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480015816.XA 2013-03-15 2014-03-13 Mir-145的锁定核酸抑制剂及其用途 Expired - Fee Related CN105188715B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800755P 2013-03-15 2013-03-15
US61/800,755 2013-03-15
PCT/US2014/026538 WO2014151835A1 (en) 2013-03-15 2014-03-13 Locked nucleic acid inhibitor of mir-145 and uses thereof

Publications (2)

Publication Number Publication Date
CN105188715A CN105188715A (zh) 2015-12-23
CN105188715B true CN105188715B (zh) 2018-12-25

Family

ID=51581048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015816.XA Expired - Fee Related CN105188715B (zh) 2013-03-15 2014-03-13 Mir-145的锁定核酸抑制剂及其用途

Country Status (6)

Country Link
US (1) US9752143B2 (enExample)
EP (1) EP2968396B1 (enExample)
JP (1) JP6410791B2 (enExample)
CN (1) CN105188715B (enExample)
CA (1) CA2902623A1 (enExample)
WO (1) WO2014151835A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241296B2 (en) 2005-11-17 2022-02-08 Breast-Med, Inc. Imaging fiducial markers and methods
WO2017184751A1 (en) * 2016-04-20 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing hypertension
WO2018079841A1 (ja) * 2016-10-31 2018-05-03 国立大学法人岐阜大学 二本鎖核酸分子、およびその用途
EP4279091A4 (en) * 2021-01-18 2024-12-11 Regen Innopharm Inc. Composition comprising mir 145 inhibitor as active ingredient for treatment of myocardial infarction
WO2025008641A2 (en) * 2023-07-06 2025-01-09 Imperial College Innovations Limited Rna molecule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112754A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
WO2012153135A1 (en) * 2011-05-09 2012-11-15 University Of Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003843A1 (en) 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7803782B2 (en) 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
YU73600A (sh) 1998-05-26 2003-08-29 Icn Pharmaceuticals Inc. Novi nukleosidi koji imaju biciklične šećerne grupe
US6833361B2 (en) 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
WO2000056916A2 (en) 1999-03-18 2000-09-28 Exiqon A/S Detection of mutations in genes by specific lna primers
DE60119562T2 (de) 2000-10-04 2007-05-10 Santaris Pharma A/S Verbesserte synthese von purin-blockierten nukleinsäure-analoga
US20050124566A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP2428568B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
US7781415B2 (en) 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
KR20050115231A (ko) 2003-02-10 2005-12-07 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 포유동물 세포의 조절
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
WO2005082440A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
EP2808389A1 (en) 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
CA2603881A1 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
EP2497827A1 (en) 2005-12-12 2012-09-12 University Of North Carolina At Chapel Hill Micro-RNAs that regulate muscle cell proliferation and differentiation
RU2008141688A (ru) 2006-04-21 2010-04-27 ДжФЕ СТИЛ КОРПОРЕЙШН (JP) Дисковые тормоза, обладающие высоким сопротивлением смягчающему отпуску
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
ES2406686T3 (es) * 2007-10-04 2013-06-07 Santaris Pharma A/S Micromirs
EP2279267A4 (en) 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
US8735568B2 (en) * 2009-03-09 2014-05-27 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
CA2761106C (en) 2009-05-05 2019-01-15 Miragen Therapeutics Lipophilic polynucleotide conjugates
AU2010258875A1 (en) 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
CN102382824A (zh) 2010-09-01 2012-03-21 中国科学院上海药物研究所 人miR-145反义核酸及其应用
AR084319A1 (es) * 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112754A2 (en) * 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
WO2012153135A1 (en) * 2011-05-09 2012-11-15 University Of Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A Role for miR-145 in Pulmonary Arterial Hypertension Evidence From Mouse Models and Patient Samples;Paola Caruso, et al.;《Circulation Research》;20120720;第111卷(第3期);290-200 *

Also Published As

Publication number Publication date
EP2968396A4 (en) 2016-08-17
WO2014151835A1 (en) 2014-09-25
CA2902623A1 (en) 2014-09-25
JP6410791B2 (ja) 2018-10-24
EP2968396B1 (en) 2018-12-19
CN105188715A (zh) 2015-12-23
US20160010091A1 (en) 2016-01-14
EP2968396A1 (en) 2016-01-20
US9752143B2 (en) 2017-09-05
JP2016518820A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
JP6208228B2 (ja) ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
CN105188715B (zh) Mir-145的锁定核酸抑制剂及其用途
US9163235B2 (en) Inhibitors of the miR-15 family of micro-RNAs
JP6049700B2 (ja) 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法
EP2385120A1 (en) Use of anti-miRNA antisense oligonucleotides for the treatment of pulmonary hypertension
AU2022203361A1 (en) Compositions and methods for modulating RNA
JP2013511964A (ja) ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用
KR20150006742A (ko) 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
CN108025017A (zh) MiR-19调节剂及其用途
CN108210510A (zh) 一种小干扰核酸药物组合物及其用途
CN113476606B (zh) Upk1a-as1抑制剂在制备抗肿瘤药物中的应用
WO2018183127A1 (en) Mir-92 inhibitors for treatment of heart failure
US8765707B2 (en) MicroRNA-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
CN109674791B (zh) 噻唑并吡喃酮类似物在制备抗肝纤维化或抗急性肝损伤药物中的应用
US9617538B2 (en) Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
US20230181613A1 (en) Inhibitors of micro-rna 22
EP4269586A1 (en) Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)
US20220267778A1 (en) Nucleic acid drug targeting murf1
HK1227705A1 (en) New production method of lipoplex for local administration and antitumor drug using lipoplex
HK1227705B (en) New production method of lipoplex for local administration and antitumor drug using lipoplex

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181225

Termination date: 20210313

CF01 Termination of patent right due to non-payment of annual fee